Institution
Xuzhou Medical College
Education•Xuzhou, China•
About: Xuzhou Medical College is a education organization based out in Xuzhou, China. It is known for research contribution in the topics: Cancer & Cell growth. The organization has 12721 authors who have published 7802 publications receiving 102970 citations.
Topics: Cancer, Cell growth, Apoptosis, Medicine, Protein kinase B
Papers published on a yearly basis
Papers
More filters
••
TL;DR: XIST can positively regulate neuropathic pain in rats through regulating the expression of miR‐137 and TNFAIP1 and the results imply that XIST/miR‐ 137/TNFAip1 axis may serve as a novel therapeutic target in neuropathicPain.
Abstract: Non-coding RNAs have been reported to participate in the pathophysiology of neuropathic pain. The objective of our study was to investigate the biological role of XIST in neuropathic pain development. In our study, we identify and validate that lncRNA XIST was markedly increased and miR-137 was significantly decreased in chronic constriction injury (CCI) rats. XIST silencing alleviated pain behaviors including both mechanical and thermal hyperalgesia in the CCI rats. XIST was predicted to interact with miR-137 by bioinformatics technology and dual-luciferase reporter assays confirmed the correlation between XIST and miR-137. miR-137 was negatively modulated by XIST and upregulation of miR-137 greatly reduced neuropathic pain development in CCI rats. Moreover, we observed that tumor necrosis factor alpha-induced protein 1 (TNFAIP1) was enhanced in CCI rats and 3'-untranslated region (UTR) of TNFAIP1 was exhibited to be a target of miR-137 by bioinformatics prediction. TNFAIP1 can act as a crucial inflammation regulator by activating NF-kB activity. Overexpression of miR-137 significantly suppressed TNFAIP1 both in vitro and in vivo. Furthermore, upregulation of XIST reversed the inhibitory role of miR-137 in neuropathic pain development by inhibiting TNFAIP1. In conclusion, our current study indicates that XIST can positively regulate neuropathic pain in rats through regulating the expression of miR-137 and TNFAIP1. Our results imply that XIST/miR-137/TNFAIP1 axis may serve as a novel therapeutic target in neuropathic pain.
42 citations
••
TL;DR: RelB-silenced DCs provide a practical means to normalize the differentiation of the four T-cell subsets in vivo, and thus possess therapeutic potential in Th1/Th17-dominant autoimmune disorders such as myasthenia gravis.
Abstract: Objective
To observe the therapeutic effect of RelB-silenced dendritic cells (DCs) in experimental autoimmune myasthenia gravis (EAMG), and further to investigate the mechanism of this immune system therapeutic.
42 citations
••
TL;DR: This study reveals a requirement of Smad4 for T-cell-mediated autoimmunity and tumor rejection, which is beyond the current paradigm, and highlights a TGF-βR-independent role for Smad 4 in promoting T cell function, autoIMmunity, and anti-tumor immunity.
42 citations
••
TL;DR: The data described in this study suggest that HOTTIP may be an oncogene and a potential target in CRC.
42 citations
••
TL;DR: In this article, a new qPCR-based assay combining the detection of methylated SEPT9 and SDC2 (ColoDefense test) was used for early stage colorectal cancer diagnosis and screening.
Abstract: Methylated SEPT9 showed relatively low sensitivity in detecting early stage colorectal cancer (CRC) and advanced adenomas (AA) in plasma. Combination of multiple biomarkers was an effective strategy to improve sensitivity in early stage cancer diagnosis and screening. A new qPCR-based assay combining the detection of methylated SEPT9 and SDC2 (ColoDefense test) was used. Methylation statuses of SEPT9 and SDC2 were examined in 40 sets of cancer tissues and paired adjacent tissues, 10 adenomatous polyps and 3 hyperplastic polyps (HP). Then evaluated with 384 plasma samples, including 117 CRC patients, 23 AA patients, 78 small polyps patients, and 166 normal individuals. The limit of detection of ColoDefense was about 25 pg per reaction. Both SEPT9 and SDC2 were shown by ColoDefense to be heavily methylated in CRC tissues when compared to paired paracancerous tissues and HP (P < .01). The sensitivities for detecting AA and stage I CRC by plasma SEPT9 methylation alone were 12.1% and 65.0%, and those by plasma SDC2 methylation alone were 43.5% and 55.0%. In comparison, the sensitivities to detect AA and stage I CRC by ColoDefense improved to 47.8% and 80.0%. The overall sensitivity of ColoDefense in detecting CRC was 88.9% (95% CI: 81.4%-93.7%) with a specificity of 92.8% (95% CI: 87.4%-96.0%). Detection of the combinatorial biomarker of methylated SEPT9 and/or SDC2 is a powerful, convenient and highly effective strategy for early CRC screening with high sensitivity and specificity.
41 citations
Authors
Showing all 12775 results
Name | H-index | Papers | Citations |
---|---|---|---|
Liang Wang | 98 | 1718 | 45600 |
Chang Liu | 97 | 1099 | 39573 |
Wei Wang | 95 | 3544 | 59660 |
Yu Liu | 66 | 1262 | 20577 |
Deling Kong | 65 | 388 | 16515 |
Zhimou Yang | 61 | 222 | 12522 |
Xu-Feng Huang | 61 | 332 | 13074 |
Guangming Lu | 60 | 476 | 13218 |
Dan Ding | 59 | 212 | 12494 |
Jian Cao | 58 | 486 | 11074 |
Yuanjin Zhao | 57 | 328 | 12076 |
Jie Yang | 56 | 488 | 11382 |
Lei Wang | 54 | 1076 | 15189 |
Xiaodong Shi | 52 | 323 | 8910 |
Wei Pan | 50 | 408 | 9037 |